Trending Now
today
Welcome to Inside Wall Street, your home for all things economic, technical, and commercial.
headlines
around the world
Spark Therapeutics (NASDAQ: ONCE) gained the first Food and Drug Administration approval for a gene therapy on Tuesday — a one-time treatment for an eye disease that generally progresses to complete blindness.
The therapy, dubbed Luxturna, is the first gene therapy approved for a genetic disease and the only treatment...
